Loading...
•
Mar 31, 2020
EyePoint Pharmaceuticals Q1 2020 Earnings Report
Reported financial results for the first quarter ended March 31, 2020 and highlighted recent corporate developments.
Key Takeaways
EyePoint Pharmaceuticals reported total net revenue of $7.5 million for the first quarter ended March 31, 2020, compared to $2.0 million for the same period in 2019. Net product revenue was $4.7 million, with $3.6 million from YUTIQ and $1.1 million from DEXYCU. The company's cash and cash equivalents totaled $26.3 million at the end of the quarter.
Total revenues reached $7.5 million, with net product revenues of $4.7 million.
YUTIQ generated $3.6 million in net product revenue, while DEXYCU contributed $1.1 million.
Operating expenses increased to $18.9 million due to higher sales and marketing and research and development costs.
Cash and cash equivalents totaled $26.3 million at March 31, 2020.
Revenue by Segment
Forward Guidance
The Company expects that its cash and cash equivalents combined with projected cash inflows from anticipated YUTIQ and DEXYCU product sales can fund the Company’s operating plan into 2021 under current assumptions for the duration of the COVID-19-related closures across the U.S.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...